Use of allopurinol in children with acute lymphoblastic leukemia to reduce skewed thiopurine metabolism

Pediatric Blood and Cancer

Volumn 61, Issue 6, 2014, Pages 1114-1117

  Brackett, Julienne ^a   Schafer, Eric S ^a   Leung, Daniel H ^a   Bernhardt, M Brooke ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

Acute lymphoblastic leukemia; Allopurinol; Hepatotoxicity; Mercaptopurine; Thiopurine metabolites

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOPURINOL; HEPATOTOXICITY; MERCAPTOPURINE; THIOPURINE METABOLITES;

6-MERCAPTOPURINE; ADOLESCENT; ALLOPURINOL; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOTRANSFORMATION; CHILD, PRESCHOOL; DRUG EVALUATION; DRUG-INDUCED LIVER INJURY; FEMALE; GUANINE NUCLEOTIDES; HUMANS; HYPERBILIRUBINEMIA; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; MAINTENANCE CHEMOTHERAPY; MALE; METHOTREXATE; METHYLTRANSFERASES; NEUTROPENIA; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; THIONUCLEOTIDES; XANTHINE OXIDASE;

EID: 84898792316     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24913     Document Type: Article

References (20)

1. Gurney JG, Severson RK, Davis S, et al. Incidence of cancer in children in the United States. Sex-, race-, and 1-year age-specific rates by histologic type. Cancer 1995; 75:2186-2195.
2. Relling MV, Hancock ML, Boyett JM, et al., Prognostic importance of 6-mercaptopurine intensity in acute lymphoblastic leukemia. Blood 1999; 93:2817-2823.
3. Bhatia S, Landier W, Shangguan M, et al. Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: A report for the Children's Oncology Group. J Clin Oncol 2012; 30:2094-2101.
4. Relling MV, Gardner EE, Sandborn WJ, et al. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther 2011; 89:387-391.
5. Seinen ML, van Asseldonk DP, Boer NK, et al. The effect of allopurinol and low-dose thiopurine combination therapy on the activity of three pivotal thiopurine metabolizing enzymes: Results from a prospective pharmacological study. J Crohn's Colitis 2013; 7:812-819.
6. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118:705-713.
7. Hindorf U, Lindqvist M, Peterson C, et al. Pharmacogenetics during standardized initiation of thiopurine treatment in inflammatory bowel disease. Gut 2006; 55:1423-1431.
8. Osterman MT, Kundu R, Lichtenstein GR, et al. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: A meta-analysis. Gastroenterology 2006; 130:1047-1053.
9. de Baumais TA, Fakhoury M, Medard Y, et al. Determinants of mercaptopurine toxicity in pediatric acute lymphoblastic leukemia maintenance therapy. Br J Clin Pharmacol 2011; 71:575-584.
10. Sparrow MP, Hande SA, Friedman S, et al. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther 2005; 22:441-446.
11. Govani SM, Higgins PD. Combination of thiopurines and allopurinol: Adverse events and clinical benefit in IBD. J Crohns Colitis 2010; 4:444-449.
12. Gardiner SJ, Gearry RB, Burt MJ, et al. Allopurinol might improve response to azathioprine and 6-mercaptopurine by correcting an unfavorable metabolite ratio. J Gastroenterol Hepatol 2011; 26:49-54.
13. Kennedy NA, Asser TL, Mountifield RE, et al. Thiopurine metabolite measurement leads to changes in management of Inflammatory Bowel Disease. Int Med J 2013; 43:278-286.
14. Ansari A, Patel N, Sanderson J, et al. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2010; 31:640-647.
15. Hoentjen F, Seinen ML, Hanauer SB, et al. Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis 2013; 19:363-369.
16. Ansari A, Aslam Z, De Sica A, et al. Influence of xanthine oxidase on thiopurine metabolism in Crohn's disease. Aliment Pharmacol Ther 2008; 28:749-757.
17. Ding L, Zhang FB, Liu H, et al. Hypoxanthine guanine phosphoribosyltransferase activity is related to 6-thioguanine nucleotide concentrations and thiopurine-induced leukopenia in the treatment of inflammatory bowel disease. Inflamm Bowel Dis 2012; 18:63-73.
18. Blaker PA, Arenas-Hernandez M, Smith MA, et al. Mechanisms of allopurinol induced TPMT inhibition. Biochem Pharmacol 2013; 86:539-547.
19. U. S. Department of Health and Human Resources. Common Terminology Criteria for Adverse Events, CTCAE version 4.0. U.S. Department of Health and Human Resources; 2009. Available at: http://evs.nci.nih.gov/ftp1/CTCAE/About.html Accessed July 29, 2013.
20. Zimm S, Collins JM, O'Neill D, et al. Inhibition of first-pass metabolism in cancer chemotherapy: Interaction of 6-mercaptopurine and allopurinol. Clin Pharmocol Ther 1983; 34:810-817.